Last reviewed · How we verify
relapsed or refractory CD33-positive AML
Approved treatments
- Mylotarg · Wyeth Pharms Inc
Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them.
Clinical guidelines
- FDA label — 2L
MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- relapsed or refractory CD33-positive AML patent landscape — cliff calendar, originator estates, attackable patents
- relapsed or refractory CD33-positive AML treatment landscape brief
- relapsed or refractory CD33-positive AML treatment updates RSS
Frequently asked questions about relapsed or refractory CD33-positive AML
What drugs treat relapsed or refractory CD33-positive AML?
Tracked treatments include Mylotarg.
What is the treatment for relapsed or refractory CD33-positive AML?
Standard treatment for relapsed or refractory CD33-positive AML includes Mylotarg. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for relapsed or refractory CD33-positive AML?
FDA label publishes guidelines for relapsed or refractory CD33-positive AML. 1 guideline references tracked.
Related
- Treatment landscape: relapsed or refractory CD33-positive AML patent cliff · relapsed or refractory CD33-positive AML CI report
- Treatment: Mylotarg · Wyeth Pharms Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing